Latest evidence on gout management: what the clinician needs to know

Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial

(2012) H. Ralph Schumacher et al.   ARTHRITIS AND RHEUMATISM

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

(2011) N. Schlesinger et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduction of in vitro invasion and in vivo cartilage degradation in a SCID mouse model by loss of function of the fibrinolytic system of rheumatoid arthritis synovial fibroblasts

(2011) Simona Serratì et al.   ARTHRITIS AND RHEUMATISM

Inflammatory Gout: Observations over a Half-Century

(2011) Stephen E. Malawista et al.   FASEB JOURNAL

Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

(2011)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Epidemiology of Uric Acid and Fructose

(2011) Young Hee Rho et al.   SEMINARS IN NEPHROLOGY

Cross-sectional analysis of foot function, functional ability, and health-related quality of life in older people with disabling foot pain

(2011) Karen J. Mickle et al.   ARTHRITIS CARE & RESEARCH

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

(2011) Naomi Schlesinger et al.   ARTHRITIS RESEARCH & THERAPY

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

(2010) Robert A. Terkeltaub et al.   ARTHRITIS AND RHEUMATISM

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

(2010) Alexander So et al.   ARTHRITIS AND RHEUMATISM

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

(2010) Lisa K. Stamp et al.   ARTHRITIS AND RHEUMATISM

A prescription for lifestyle change in patients with hyperuricemia and gout

(2010) Hyon K Choi   CURRENT OPINION IN RHEUMATOLOGY

Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome

(2010) Ioannis Mitroulis et al.   European Journal of Internal Medicine

Gout therapeutics: new drugs for an old disease

(2010) Christopher M Burns et al.   LANCET

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

(2010) Michael A Becker et al.   ARTHRITIS RESEARCH & THERAPY

Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis

(2009) R Torres et al.   ANNALS OF THE RHEUMATIC DISEASES

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

(2009) R Terkeltaub et al.   ANNALS OF THE RHEUMATIC DISEASES

Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout

(2009) William John Martin et al.   ARTHRITIS AND RHEUMATISM

Use of imaging to evaluate gout and other crystal deposition disorders

(2009) Nicola Dalbeth et al.   CURRENT OPINION IN RHEUMATOLOGY

A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout

(2009) Ming-Han H Lee et al.   DRUG SAFETY

Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout

(2009) M. A. BECKER et al.   JOURNAL OF RHEUMATOLOGY

Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

(2009) H. R. Schumacher et al.   RHEUMATOLOGY

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study

(2008) John S. Sundy et al.   ARTHRITIS AND RHEUMATISM

Resolution of gouty tophi after twelve weeks of pegloticase treatment

(2008) Herbert S. B. Baraf et al.   ARTHRITIS AND RHEUMATISM

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial

(2008) H. RALPH Schumacher et al.   ARTHRITIS AND RHEUMATISM

Plasma Urate Level Is Directly Regulated by a Voltage-driven Urate Efflux Transporter URATv1 (SLC2A9) in Humans

(2008) Naohiko Anzai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Urate Transport Across the Apical Membrane of Renal Proximal Tubules

(2008) Hitoshi Endou et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout

(2008) N. Dalbeth et al.   RHEUMATOLOGY

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

(2007) Merry R. Sherman et al.   ADVANCED DRUG DELIVERY REVIEWS